Drug intelligence / Profile preview

DESCARTES-33

Development stage: Preclinical
Lead developer: Cartesian Therapeutics
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Parenteral

Overview

DESCARTES-33 is an off-the-shelf, allogeneic, RNA-engineered mesenchymal stem cell (MSC) therapy being developed by Cartesian Therapeutics, leveraging its proprietary RNA Armory platform. This therapy is being investigated as a treatment for autoimmune diseases. The RNA engineering of the MSCs is designed to enable targeted immunomodulation for disease processes in autoimmune conditions. As of the latest public information, DESCARTES-33 is in preclinical development.

Brand names: DESCARTES-33DESCARTES33DESCARTES 33
Other names: DESCARTES-33DESCARTES33DESCARTES 33

Beyond the preview

Go deeper on DESCARTES-33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DESCARTES-33.

Explore the full profile